Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma
Patrick M McCarthy,Matthew J Rendo,Matthew D Uy,Alexandra M Adams,Anne E O’Shea,Daniel William Nelson,Joshua L Fenderson,Katherine M Cebe,Robert W Krell,Guy T Clifton,George E Peoples,Timothy J Vreeland
DOI: https://doi.org/10.2147/OTT.S311661
IF: 4
2021-06-01
OncoTargets and Therapy
Abstract:Patrick M McCarthy, 1 Matthew J Rendo, 2 Matthew D Uy, 3 Alexandra M Adams, 1 Anne E O'Shea, 1 Daniel William Nelson, 4 Joshua L Fenderson, 2 Katherine M Cebe, 3 Robert W Krell, 1 Guy T Clifton, 1 George E Peoples, 5 Timothy J Vreeland 1 1 Department of Surgery, Brooke Army Medical Center, San Antonio, TX, USA; 2 Department of Hematology and Oncology, Brooke Army Medical Center, San Antonio, TX, USA; 3 Department of Pathology, Brooke Army Medical Center, San Antonio, TX, USA; 4 Department of Surgery, William Beaumont Army Medical Center, El Paso, TX, USA; 5 Cancer Vaccine Development Program, San Antonio, TX, USA Correspondence: Patrick M McCarthy Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Dr., San Antonio, TX, 78234, USA Tel +1 240 285-0930 Fax +1 210 916-6658 Email Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC. Keywords: pancreatic cancer, pembrolizumab, complete response, PD-L1, locally advanced, immune checkpoint inhibitor Pancreatic ductal adenocarcinoma (PDAC) is difficult to treat; the 5 year-survival rate across all stages is 7.9% in the United States. 1 Approximately 20% of patients are candidates for surgical intervention at the time of diagnosis. 2 , 3 As a result, there has been increasing interest in expanding the armamentarium of neoadjuvant therapies aimed at decreasing tumor burden and selecting patients with favorable tumor biology prior to curative-intent surgery, particularly for locally advanced 4–7 and borderline resectable 8–12 PDAC. In contrast to breast, rectal, and esophageal cancers, complete pathologic responses to neoadjuvant chemotherapy occur in only 5–7.5% of cases. 13 , 14 Cancer patients have benefited from the development and expansion of personalized medicine and immunotherapy, particularly with the use of immune checkpoint inhibitors (ICI). Drugs targeting CTLA-4, PD-1, and PD-L1 have been far more effective in the management of melanoma 15–17 and lung cancer 18–22 than cytotoxic chemotherapy alone. The success of ICI in these settings has led to expanded use of these immunotherapies across diverse tumor types. Recently, pembrolizumab received FDA approval for treating metastatic cancers with either high microsatellite instability (MSI-H) 23 or high tumor mutational burden-high (TMB-H), regardless of histology. 24 , 25 These and other trials targeting tumor biology or gene expression over specific histologic origin highlight a major paradigm shift in cancer treatment. Despite this enthusiasm for immune therapy, outcomes with ICI in PDAC patients have been less impressive. In the KEYNOTE-158 trial, even amongst PDAC tumors that were MSI-H/dMMR, overall response rate to pembrolizumab monotherapy was 18.2%; the lowest of all GI tract malignancies. 24 While the results of immunotherapy in PDAC have by and large been unimpressive, it is possible that it may still have a role in correctly selected patients. Here, we present the case of a patient with locally advanced PDAC and near pathologic complete response (pCR) after administration of combination pembrolizumab and radiation therapy (RT) and a review of the available literature on the use of personalized medicine and immunotherapy in PDAC. All information in this project was obtained in accordance with the Declaration of Helsinki, HIPAA, and our institutional guidelines. The patient described in this case has given informed consent and consent to publish the clinical details contained within this report. Institutional approval was not required to publish the details of the case included in this report. -Abstract Truncated-
oncology,biotechnology & applied microbiology